Blood cancers

When do we manage CLL as a chronic disease and when do we aim for cure?

Sponsored by Janssen-Cilag Pty Ltd

Developing tools that enable clinicians to predict which subgroups of patients can be cured and which will require ongoing treatment is critical in optimising outcomes in patients with chronic lymphocytic leukaemia (CLL), Professor Peter Hillmen, Haematologist at St James University Hospital in Leeds, UK, told delegates at the Janssen H3 conference held in Sydney last ...

Already a member?

Login to keep reading.

© 2021 the limbic